Evidence map›Paper›PMID 38380705›Full record

ArticleProtein science : a publication of the Protein Society2024

Degradation versus fibrillogenesis, two alternative pathways modulated by seeds and glycosaminoglycans.

Guglielmo Verona, Sara Raimondi, Diana Canetti, P Patrizia Mangione, Loredana Marchese, Alessandra Corazza, Francesca Lavatelli, Julian D Gillmore, Graham W Taylor, Vittorio Bellotti and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Guglielmo VeronaCentre for Amyloidosis, University College London, London, UK.
Sara RaimondiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Diana CanettiCentre for Amyloidosis, University College London, London, UK.
P Patrizia MangioneDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Loredana MarchesePathology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Alessandra CorazzaDepartment of Medicine (DAME), University of Udine, Udine, Italy.ORCID 0000-0003-2272-1928
Francesca LavatelliDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.
Julian D GillmoreCentre for Amyloidosis, University College London, London, UK.
Graham W TaylorCentre for Amyloidosis, University College London, London, UK.
Vittorio BellottiResearch Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Sofia GiorgettiDepartment of Molecular Medicine, University of Pavia, Pavia, Italy.ORCID 0000-0001-9438-6511
University of Pavia · ITAmyloidosis Foundation · USPoliclinico San Matteo Fondazione · ITUniversity of Udine · IT

Funding

Cariplo-Telethon Joint Call for Applications 2022-0578Fondazione Cariplo 2022-0535Istituto Nazionale di Biostrutture e Biosistemi (INBB)Italian Ministry of Research and University Dipartimenti di Eccellenza 2018-2022/2022-2027Pfizer 2021-67456913PNRR Grant CN3 National Center for Gene Therapy and Drugs based on RNA Technology CN00000041U.K. Medical Research Council MR/R016984/1University College London Technology Fund
6 · The paper itself

Abstract

The mechanism that converts native human transthyretin into amyloid fibrils in vivo is still a debated and controversial issue. Commonly, non-physiological conditions of pH, temperature, or organic solvents are used in in vitro models of fibrillogenesis of globular proteins. Transthyretin amyloid formation can be achieved under physiological conditions through a mechano-enzymatic mechanism involving specific serine proteases such as trypsin or plasmin. Here, we investigate S52P and L111M transthyretin variants, both causing a severe form of systemic amyloidosis mostly targeting the heart at a relatively young age with heterogeneous phenotype among patients. Our studies on thermodynamics show that both proteins are significantly less stable than other amyloidogenic variants. However, despite a similar thermodynamic stability, L111M variant seems to have enhanced susceptibility to cleavage and a lower tendency to form fibrils than S52P in the presence of specific proteases and biomechanical forces. Heparin strongly enhances the fibrillogenic capacity of L111M transthyretin, but has no effect on the S52P variant. Fibrillar seeds similarly affect the fibrillogenesis of both proteins, with a stronger effect on the L111M variant. According to our model of mechano-enzymatic fibrillogenesis, both full-length and truncated monomers, released after the first cleavage, can enter into fibrillogenesis or degradation pathways. Our findings show that the kinetics of the two processes can be affected by several factors, such as intrinsic amyloidogenicity due to the specific mutations, environmental factors including heparin and fibrillar seeds that significantly accelerate the fibrillogenic pathway.

Indexed as

AmyloidosisGlycosaminoglycansAmyloidHeparinHumansPrealbuminAmyloidGlycosaminoglycansHeparinPrealbuminamyloidosiscardiac myopathyfibrillogenesisproteolysistransthyretin

Identifiers

PMID38380705
PMCPMC10880434
OpenAlexW4392003999

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.